Shares of Johnson & Johnson climbed 4.5% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for the biggest one-day gain since they rallied 4.6% on May 1, 2024.

Alright, listen to me. This one is one that everyone’s going to give up on. Then one day, it’s going to be up 300, I’m not ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Cantor Fitzgerald cut Eli Lilly’s FY2025 earnings forecast from $21.91 to $21.76 per share. Eli Lilly reported $3.34 per ...

The gene editing company has seen its shares surge approximately 160% since mid-June, building on momentum that began after a ...

Our Top 5 Analyst Questions Eli Lilly’s Q1 Earnings Call Asad Haider (Goldman Sachs) asked about the impact of the CVS formulary loss on Zepbound’s market share and future PBM dynamics.

One of the standouts of today's afternoon trading session has been Eli Lilly and, which logged a -7.3% drop and underperformed the S&P 500 by -7.0%. The Pharmaceutical stock is now trading at $739.22 ...

Friday, June 13, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Eli Lilly ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. However, the guidance ...